

# Larry Norton

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8953280/larry-norton-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291  
papers

48,021  
citations

88  
h-index

218  
g-index

323  
ext. papers

53,657  
ext. citations

10.1  
avg, IF

6.72  
L-index

#	Paper	IF	Citations
291	Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 14	7.8	
290	Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 21	7.8	1
289	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 37	7.8	0
288	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 50	7.8	0
287	Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. <i>Npj Genomic Medicine</i> , <b>2021</b> , 6, 99	6.2	1
286	Clonal hematopoiesis is associated with risk of severe Covid-19. <i>Nature Communications</i> , <b>2021</b> , 12, 5975	17.4	12
285	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 43	7.8	3
284	Anti-tumor effects of an ID antagonist with no observed acquired resistance. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 58	7.8	0
283	Stochastic Norton-Simon-Massagué Tumor Growth Modeling: Controlled and Mixed-Effect Uncontrolled Analysis. <i>IEEE Transactions on Control Systems Technology</i> , <b>2021</b> , 29, 704-717	4.8	
282	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , <b>2021</b> , 15, 1024-1039	7.9	6
281	Comparative Effectiveness Research Needs to Consider Optimal Dosing and Scheduling. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 253-254	2.2	1
280	Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2034045	10.4	6
279	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 96	7.8	7
278	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1139-1150	21.7	24
277	The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1301-1311	21.7	1
276	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , <b>2021</b> ,	9.8	3
275	Fractional SIR epidemiological models. <i>Scientific Reports</i> , <b>2020</b> , 10, 20882	4.9	7

274	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 227-241	4	11
273	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5178-5187	12.9	8
272	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , <b>2020</b> , 33, 2221-2232	9.8	10
271	Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , <b>2020</b> , 1, 382-393	15.4	49
270	Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	1
269	Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	
268	Fractional SIR Epidemiological Models <b>2020</b> ,		2
267	Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 107-110	9.7	4
266	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With /CEP17 Ratio . <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 597-601	5	9
265	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4120-4129	2.2	7
264	Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. <i>Histopathology</i> , <b>2020</b> , 77, 321-326	7.3	4
263	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , <b>2020</b> , 52, 1219-1226	12.6	103
262	Reply to "Multicentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomas". <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 310-311	3.1	
261	The Landscape of Somatic Genetic Alterations in Breast Cancers from Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz027	4.6	7
260	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. <i>Cancer Research</i> , <b>2019</b> , 79, 4315-4323	4.2	4
259	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 177, 61-66	4.4	23
258	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3784-3792	12.9	17
257	Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 724-728	5.1	26

256	p21CIP1 Promotes Mammary Cancer-Initiating Cells via Activation of Wnt/TCF1/CyclinD1 Signaling. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 1571-1581	6.6	7
255	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , <b>2019</b> , 393, 1440-1452	4.0	137
254	Homologous recombination DNA repair defects in associated breast cancers. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 23	7.8	20
253	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2338-2348	2.2	25
252	Paradigms for Precision Medicine in Epithelial Cancer Therapy. <i>Cancer Cell</i> , <b>2019</b> , 36, 559-573.e7	24.3	25
251	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , <b>2019</b> , 24, e646-e652	5.7	3
250	Multisystem Toxicity in Cancer: Lessons from NASA's Countermeasures Program. <i>Cell</i> , <b>2019</b> , 179, 1003-1009	10.9	11
249	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1916211	10.4	5
248	The Genomic Landscape of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 737-741	9.7	41
247	Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 329-335	3.1	5
246	The 21-Gene Recurrence Score in Male Breast Cancer. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 1530-1535	3.1	9
245	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1030-1034	9.7	65
244	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, 387-394	3	14
243	Sleep problems in breast cancer survivors 1-10 years posttreatment. <i>Palliative and Supportive Care</i> , <b>2018</b> , 16, 325-334	2.5	45
242	An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis. <i>Cancer Research</i> , <b>2018</b> , 78, 103-114	10.1	9
241	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. <i>BMC Cancer</i> , <b>2018</b> , 18, 42	4.8	7
240	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , <b>2018</b> , 9, 1816	17.4	82
239	MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. <i>Journal of Pathology</i> , <b>2018</b> , 244, 143-150	9.4	46

238	Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 4141	17.4	90
237	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , <b>2018</b> , 34, 427-438	24.6	339
236	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , <b>2018</b> , 9, 3533	17.4	60
235	Genetic analysis of uterine adenocarcinomas and phyllodes tumors of the breast. <i>Molecular Oncology</i> , <b>2017</b> , 11, 913-926	7.9	6
234	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , <b>2017</b> , 23, 376-385	50.5	82
233	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3859-3870	12.9	92
232	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. <i>Oncologist</i> , <b>2017</b> , 22, 139-143	5.7	21
231	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 165, 65-76	4.4	18
230	Dealing with the tyranny of certainty in the (medical) digital age. <i>Psycho-Oncology</i> , <b>2017</b> , 26, 147-148	3.9	
229	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4402-4415	12.9	69
228	The genetic landscape of breast carcinomas with neuroendocrine differentiation. <i>Journal of Pathology</i> , <b>2017</b> , 241, 405-419	9.4	35
227	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. <i>Nature Communications</i> , <b>2017</b> , 8, 857	17.4	129
226	Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E9066-E9075	11.5	317
225	American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2203-2208	22.08	100
224	Diverse and Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6708-6720	12.9	132
223	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 48	7.8	38
222	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 166, 69-76	4.4	22
221	Breast carcinoma with an Oncotype Dx recurrence score . <i>Cancer</i> , <b>2017</b> , 123, 131-137	6.4	14

220	A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2017</b> , 17, e37-e41	3	12
219	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , <b>2017</b> , 30, 69-84	9.8	34
218	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5729-5737	12.9	109
217	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 835-844	12.5	95
216	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. <i>Science Signaling</i> , <b>2016</b> , 9, ra33	8.8	41
215	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review. <i>Npj Breast Cancer</i> , <b>2016</b> , 2, 16006	7.8	8
214	Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 157, 395-400	4.4	17
213	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2359-65	2.2	40
212	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2016</b> , 16, 87-94	3	1
211	Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1030-3	2.2	60
210	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4045-56	12.9	85
209	Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. <i>Genes and Development</i> , <b>2016</b> , 30, 34-51	12.6	374
208	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. <i>Clinical Breast Cancer</i> , <b>2016</b> , 16, 276-83	3	9
207	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , <b>2016</b> , 238, 508-18	9.4	80
206	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , <b>2016</b> , 2,	7.8	58
205	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. <i>Npj Breast Cancer</i> , <b>2016</b> , 2, 16035	7.8	23
204	TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. <i>Npj Breast Cancer</i> , <b>2016</b> , 2, 16009	7.8	14
203	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , <b>2016</b> , 29, 476-88	9.8	67

202	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1267-1275	24.4	30
201	Disabling of the erbB Pathway Followed by IFN- $\gamma$ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. <i>Cell Reports</i> , <b>2015</b> , 12, 2049-59	10.6	18
200	Genomic landscape of adenoid cystic carcinoma of the breast. <i>Journal of Pathology</i> , <b>2015</b> , 237, 179-89	9.4	101
199	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. <i>Genome Biology</i> , <b>2015</b> , 16, 107	18.3	83
198	Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].. <i>Modern Pathology</i> , <b>2015</b> , 28, 340-51	9.8	56
197	Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites. <i>Npj Breast Cancer</i> , <b>2015</b> , 1, 15018	7.8	25
196	Cell-to-cell communication in cancer: workshop report. <i>Npj Breast Cancer</i> , <b>2015</b> , 1, 15022	7.8	1
195	Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients <b>2015</b> , 3,		8
194	Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis. <i>Npj Breast Cancer</i> , <b>2015</b> , 1, 15010	7.8	5
193	Somatic mutations in leukocytes infiltrating primary breast cancers. <i>Npj Breast Cancer</i> , <b>2015</b> , 1, 15005	7.8	18
192	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , <b>2015</b> , 237, 166-78	9.4	42
191	Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. <i>Molecular Oncology</i> , <b>2015</b> , 9, 128-39	7.9	72
190	Current management of lesions associated with an increased risk of breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 227-38	19.4	77
189	Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 442-7	2.2	63
188	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , <b>2014</b> , 46, 1166-9	36.3	150
187	Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis. <i>Cancer Research</i> , <b>2014</b> , 74, 3695-706	10.1	32
186	Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2311-7	2.2	60
185	Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) <b>2014</b> , 2,		78

184	Cancer log-kill revisited. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , 3-7	7.1	9
183	Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. <i>PLoS ONE</i> , <b>2014</b> , 9, e114900	3.7	48
182	The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	79
181	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. <i>Genome Biology</i> , <b>2014</b> , 15, 484	18.3	95
180	Advances in managing breast cancer: a clinical update. <i>F1000prime Reports</i> , <b>2014</b> , 6, 66		9
179	The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. <i>Neoplasia</i> , <b>2013</b> , 15, 848-62	6.4	289
178	TGF- $\beta$ 1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. <i>Cell Reports</i> , <b>2013</b> , 5, 1228-42	10.6	175
177	Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2013</b> , 13, 239-246.e1	3	25
176	Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. <i>Cancer Research</i> , <b>2013</b> , 73, 2760-9	10.1	64
175	Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae. <i>Breast Journal</i> , <b>2013</b> , 19, 285-92	1.2	56
174	Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. <i>Cancer</i> , <b>2013</b> , 119, 3943-51	6.4	16
173	Association between bone mineral density and incidence of breast cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e70980	3.7	19
172	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 111-6	4.4	17
171	Interventional immunotherapy in breast cancer. <i>Breast Cancer Management</i> , <b>2012</b> , 1, 257-260	0.7	
170	Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 135, 93-102	4.4	29
169	Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6784-91	12.9	138
168	Randomised trial of expressive writing for distressed metastatic breast cancer patients. <i>Psychology and Health</i> , <b>2012</b> , 27, 88-100	2.9	49
167	Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , <b>2012</b> , 17, 241-9	2.4	9



166	A CXCL1 paracrine network links cancer chemoresistance and metastasis. <i>Cell</i> , <b>2012</b> , 150, 165-78	56.2	720
165	Rare de novo germline copy-number variation in testicular cancer. <i>American Journal of Human Genetics</i> , <b>2012</b> , 91, 379-83	11	20
164	Reply to S. Mahesh. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4446-4446	2.2	
163	Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3148-9; author reply 3149-50	2.2	4
162	Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4071-6	2.2	69
161	Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2179-82	2.2	35
160	Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. <i>Cancer Research</i> , <b>2012</b> , 72, 430-9	10.1	205
159	Self-seeding in cancer. <i>Recent Results in Cancer Research</i> , <b>2012</b> , 195, 13-23	1.5	28
158	Clinical implications of cancer self-seeding. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 369-77	19.4	213
157	Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1-14	6.7	95
156	Tumor entrained neutrophils inhibit seeding in the premetastatic lung. <i>Cancer Cell</i> , <b>2011</b> , 20, 300-14	24.3	491
155	Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2011</b> , 11, 306-11	3	102
154	Breast cancer methylomes establish an epigenomic foundation for metastasis. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 75ra25	17.5	215
153	Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. <i>Medical Oncology</i> , <b>2011</b> , 28 Suppl 1, 533-47	3.7	12
152	Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. <i>Cancer</i> , <b>2011</b> , 117, 4125-31	6.4	13
151	Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. <i>Cancer</i> , <b>2011</b> , 117, 5461-8	6.4	66
150	Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2610-2	2.2	30
149	p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5170-8	12.9	28

148	A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3398-407	12.9	28
147	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. <i>Genes and Development</i> , <b>2011</b> , 25, 226-31	12.6	170
146	Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3490-9	12.9	109
145	HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5132-9	12.9	330
144	Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. <i>Breast Disease</i> , <b>2010</b> , 31, 7-18	1.6	27
143	Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 628-33	2.2	41
142	Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2982-8	2.2	35
141	Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2115-21	12.9	196
140	Dose-dense chemotherapy for breast cancer: what does the future hold?. <i>Future Oncology</i> , <b>2010</b> , 6, 951-65	6.5	7
139	Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. <i>Clinical Breast Cancer</i> , <b>2010</b> , 10, 440-4	4	6
138	Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 76, 1305-13	4	19
137	Role of anthracyclines in the treatment of early breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4798-808	2.2	71
136	Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6117-23	2.2	21
135	The 6q22.33 locus and breast cancer susceptibility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 2468-75	4	22
134	Latent bone metastasis in breast cancer tied to Src-dependent survival signals. <i>Cancer Cell</i> , <b>2009</b> , 16, 67-78	24.3	534
133	A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 115, 609-12	4.4	11
132	Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 113, 479-90	4.4	11
131	Tumor self-seeding by circulating cancer cells. <i>Cell</i> , <b>2009</b> , 139, 1315-26	56.2	972

130	Adjuvant chemotherapy in older women with early-stage breast cancer. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2055-65	59.2	417
129	Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. <i>Clinical Breast Cancer</i> , <b>2008</b> , 8, 418-24	3	8
128	The concept of mathematically optimised dose-scheduling as applied to the adjuvant chemotherapy of primary breast cancer: theory and recent results. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 10-16	1.6	
127	Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. <i>Cancer Treatment Reviews</i> , <b>2008</b> , 34, 223-30	14.4	10
126	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 4340-5	11.5	256
125	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1331-7	2.2	465
124	Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1948-55	2.2	156
123	SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 240-8	12.9	156
122	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1642-9	2.2	481
121	Dose-dense chemotherapy with trastuzumab is an appropriate option. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3655-6; author reply 3656	2.2	2
120	Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2659-65	2.2	24
119	Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1797-802	2.2	58
118	Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2364-72	2.2	7
117	The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1216-22	2.2	51
116	Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1803-9	2.2	127
115	A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7878-83	12.9	95
114	Cancer stem cells, self-seeding, and decremented exponential growth: theoretical and clinical implications. <i>Breast Disease</i> , <b>2008</b> , 29, 27-36	1.6	35
113	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. <i>BMC Genetics</i> , <b>2008</b> , 9, 14	2.6	30

112	Changing indications for surgery in patients with stage IV breast cancer: a current perspective. <i>Cancer</i> , <b>2008</b> , 112, 1445-54	6.4	16
111	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5287-312	2.2	1760
110	Keeping faith with trial volunteers. <i>Nature</i> , <b>2007</b> , 446, 137-8	50.4	17
109	Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 2510-8	3.1	72
108	Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2006-11	2.2	112
107	Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2977-85	12.9	73
106	Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3699-704	2.2	226
105	HER2 and response to paclitaxel in node-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1496-506	59.2	462
104	Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5410-7	2.2	288
103	Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6195-203	12.9	20
102	Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 223-7	12.9	10
101	Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. <i>Genetic Epidemiology</i> , <b>2006</b> , 30, 48-61	2.6	16
100	Pharmacokinetics and toxicity of weekly docetaxel in older patients. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6100-5	12.9	65
99	Novel patterns of genome rearrangement and their association with survival in breast cancer. <i>Genome Research</i> , <b>2006</b> , 16, 1465-79	9.7	256
98	Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. <i>Oncologist</i> , <b>2006</b> , 11, 1070-1	5.7	42
97	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1658-67	27.4	549
96	The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 406-7		141
95	A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. <i>Clinical Breast Cancer</i> , <b>2006</b> , 7, 270-7	3	76

94	Is cancer a disease of self-seeding?. <i>Nature Medicine</i> , <b>2006</b> , 12, 875-8	50.5	276
93	The MORE Trial: Multiple Outcomes for Raloxifene Evaluation. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 949, 134-142	6.5	27
92	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient perspective. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 98, 343-8	4.4	71
91	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 99, 295-300	4.4	77
90	Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 100, 301-8	4.4	20
89	Role of Modeling in Pharmacotherapeutics <b>2006</b> , 3-27		1
88	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , <b>2005</b> , 366, 2087-106	4.0	3823
87	Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1262-71	9.7	918
86	Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. <i>Cancer Investigation</i> , <b>2005</b> , 23, 483-7	2.1	32
85	Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. <i>Drugs and Aging</i> , <b>2005</b> , 22, 785-91	4.7	22
84	Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. <i>Drugs and Aging</i> , <b>2005</b> , 22, 709-15	4.7	12
83	Dose-dense adjuvant chemotherapy for primary breast cancer. <i>Breast Cancer Research</i> , <b>2005</b> , 7, 64-9	8.3	27
82	Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 1482-9	6.7	116
81	Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?. <i>Breast Journal</i> , <b>2005</b> , 11, 317-20	1.2	7
80	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. <i>Cancer</i> , <b>2005</b> , 103, 44-51	6.4	123
79	Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. <i>Cancer</i> , <b>2005</b> , 104, 1575-9	6.4	150
78	Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer. <i>Current Oncology Reports</i> , <b>2005</b> , 7, 9-11	6.3	
77	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 92, 151-6	4.4	40

76	Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1382-4	9.7	70
75	Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4287-97	2.2	96
74	Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2191-200	2.2	87
73	Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 1073-81	27.4	318
72	Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. <i>Oncologist</i> , <b>2005</b> , 10, 370-81	5.7	130
71	Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 30-40	2.2	83
70	Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5754-61	12.9	29
69	Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 4062-7	12.9	59
68	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 971-7	59.2	766
67	Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2061-8	2.2	230
66	Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). <i>Investigational New Drugs</i> , <b>2004</b> , 22, 83-9	4.3	8
65	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. <i>Cancer</i> , <b>2004</b> , 101, 926-33	6.4	47
64	A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. <i>Cancer</i> , <b>2004</b> , 101, 2509-15	6.4	39
63	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. <i>Breast Cancer Research</i> , <b>2004</b> , 6, R8-R17	8.3	225
62	Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. <i>Genome Research</i> , <b>2003</b> , 13, 2291-305	9.7	317
61	Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1548-51	9.7	160
60	Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1825-35	2.2	47
59	Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. <i>Cancer</i> , <b>2003</b> , 98, 679-89	6.4	241

58	Factors influencing treatment patterns of breast cancer patients age 75 and older. <i>Critical Reviews in Oncology/Hematology</i> , <b>2003</b> , 46, 121-6	7	112
57	Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 976-83	2.2	1050
56	A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1793-802	59.2	1500
55	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1181-90	2.2	1245
54	Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1819-24	2.2	17
53	Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1260-8	2.2	363
52	High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 743-50	2.2	58
51	Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 732-42	2.2	22
50	Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2319-26	2.2	69
49	Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3665-73	2.2	26
48	Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 18649-57	5.4	257
47	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1609-15	59.2	1198
46	Focus on breast cancer. <i>Cancer Cell</i> , <b>2002</b> , 1, 319-22	24.3	76
45	Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. <i>Cancer</i> , <b>2001</b> , 91, 443-54	6.4	178
44	Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. <i>Breast Cancer Research and Treatment</i> , <b>2001</b> , 66, 239-48	4.4	163
43	Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. <i>Breast Cancer Research and Treatment</i> , <b>2001</b> , 65, 125-34	4.4	539
42	Theoretical concepts and the emerging role of taxanes in adjuvant therapy. <i>Oncologist</i> , <b>2001</b> , 6 Suppl 3, 30-5	5.7	96
41	Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 783-92	59.2	8714

40	Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. <i>Breast Cancer Research</i> , <b>2001</b> , 3, 361-4	8.3	17
39	Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2587-95	2.2	474
38	Dose-intensity, dose-escalation, and dose-density in the adjuvant chemotherapy of primary, operable breast cancer. <i>Breast Disease</i> , <b>2001</b> , 14, 81-9	1.6	1
37	High-dose chemotherapy for breast cancer: "how do you know?". <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2769-70	2.2	11
36	Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy. <i>Oncologist</i> , <b>2001</b> , 6, 30-35	5.7	4
35	A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners. <i>Psycho-Oncology</i> , <b>2000</b> , 9, 44-56	3.9	87
34	HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3471-9	2.2	153
33	Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 14838-45	5.4	236
32	Association of angiogenesis in lymph node metastases with outcome of breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 486-92	9.7	67
31	Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. <i>Journal of Cell Biology</i> , <b>2000</b> , 148, 779-90	7.3	739
30	An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2000</b> , 46 Suppl, S23-6	3.5	4
29	A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners <b>2000</b> , 9, 44		8
28	Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 64-73	2.2	38
27	Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 2112-7	9.7	149
26	The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. <i>JAMA - Journal of the American Medical Association</i> , <b>1999</b> , 281, 2189-97	27.4	1375
25	Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. <i>Cancer Investigation</i> , <b>1998</b> , 16, 67-71	2.1	9
24	erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 1346-60	9.7	510
23	Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 1205-11	9.7	477



22	Breast cancer advocates in clinical research: a trialist's perspective. <i>Breast Disease</i> , <b>1998</b> , 10, 51-9	1.6	3
21	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. <i>Nature Genetics</i> , <b>1996</b> , 13, 126-8	36.3	252
20	The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. <i>Nature Genetics</i> , <b>1996</b> , 14, 188-90	36.3	337
19	Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. <i>New England Journal of Medicine</i> , <b>1994</b> , 330, 1253-9	59.2	554
18	Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. <i>International Journal of Clinical and Laboratory Research</i> , <b>1994</b> , 24, 6-14		71
17	Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. <i>Journal of the National Cancer Institute</i> , <b>1993</b> , 85, 1327-33	9.7	323
16	Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report. <i>Annals of the New York Academy of Sciences</i> , <b>1993</b> , 698, 398-402	6.5	1
15	An intensive sequenced adjuvant chemotherapy regimen for breast cancer. <i>Cancer Investigation</i> , <b>1993</b> , 11, 6-9	2.1	8
14	Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. <i>Journal of the National Cancer Institute</i> , <b>1993</b> , 85, 1319-26	9.7	35
13	Phase II trial of carboplatin and etoposide in metastatic breast cancer. <i>Cancer</i> , <b>1993</b> , 71, 1254-7	6.4	12
12	Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. <i>Cancer</i> , <b>1993</b> , 71, 2515-21	6.4	46
11	Chemotherapy for urothelial tract malignancies: breaking the deadlock. <i>Journal of Surgical Oncology</i> , <b>1992</b> , 8, 316-41		32
10	Adjuvant systemic therapy for early breast cancer. <i>Journal of Surgical Oncology</i> , <b>1991</b> , 7, 283-90		2
9	Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin, Dx Dx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. <i>Investigational New Drugs</i> , <b>1990</b> , 8, 221-6	4.3	4
8	Implications of growth kinetic concepts for cancer chemoprevention. <i>Cancer Investigation</i> , <b>1988</b> , 6, 625-8.1		1
7	Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. <i>Medical and Pediatric Oncology</i> , <b>1983</b> , 11, 76-8		52
6	The treatment of combination chemotherapy-resistant Hodgkin disease with single-agent vinblastine. <i>American Journal of Hematology</i> , <b>1978</b> , 4, 47-55	7.1	7
5	Growth curve of an experimental solid tumor following radiotherapy. <i>Journal of the National Cancer Institute</i> , <b>1977</b> , 58, 1735-41	9.7	98

4	Effect of prior radiotherapy on tolerance and response to chemotherapy in non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , <b>1977</b> , 2, 113-22	7.1	7
3	Predicting the course of Gompertzian growth. <i>Nature</i> , <b>1976</b> , 264, 542-5	50.4	239
2	Anti-tumor effects of an Id antagonist with no acquired resistance		3
1	Control and the Analysis of Cancer Growth Models		1